S-Acetyl Glutathione.

Cysteine is the rate-limiting amino acid for glutathione synthesis and NAC is the standard way to deliver it, so NAC feeds the de novo route while the acetylated form delivers intact tripeptide. The two raise the same pool by separate routes.

Glycine is the third amino acid ligated by glutathione synthetase, and glycine availability becomes limiting for glutathione formation in older adults, so it is a direct substrate partner.

Glutamine is deamidated to glutamate, the first amino acid in the gamma-glutamylcysteine step of glutathione synthesis, so it supplies the backbone of the tripeptide.

Dihydrolipoic acid reduces oxidised glutathione back to its active thiol form, and lipoic acid also raises cysteine availability for synthesis, so it both recycles and refills the pool.

Glutathione reduces dehydroascorbate back to ascorbate and ascorbate in turn spares glutathione, a mutual regeneration loop that is textbook antioxidant network chemistry.

Glutathione peroxidase is a selenoenzyme, so selenium availability sets how much of the glutathione pool can be used to reduce peroxides.

Selenomethionine is the food form of selenium that supplies the selenocysteine residue at the active site of glutathione peroxidase, the enzyme that spends glutathione.

Glutathione reductase is an FAD-dependent flavoenzyme, so riboflavin status determines how fast oxidised glutathione returns to its reduced form. Erythrocyte glutathione reductase activity is the standard riboflavin status marker.

Tocopherol quenches lipid radicals in membranes and the resulting tocopheroxyl radical is regenerated through ascorbate, which glutathione in turn restores, chaining the lipid and aqueous compartments together.

SAM-e sits upstream of the transsulfuration route converting homocysteine to cystathionine and then cysteine, the precursor glutathione synthesis depends on, and it activates cystathionine beta-synthase.

5-MTHF donates the methyl group that remethylates homocysteine, and how homocysteine is partitioned between remethylation and transsulfuration determines how much cysteine reaches glutathione synthesis.

Both cystathionine beta-synthase and cystathionine gamma-lyase are pyridoxal-5-phosphate dependent, so B6 status gates the transsulfuration steps producing cysteine for glutathione.

Sulforaphane modifies KEAP1 cysteines and releases Nrf2, which raises transcription of glutamate-cysteine ligase and glutathione reductase, so it raises synthesis capacity while the acetylated form raises the pool directly.

Whey is unusually rich in cystine and in glutamylcysteine bound within its beta-lactoglobulin and serum albumin fractions, the dietary route to the same rate-limiting precursor.

S-acetyl glutathione is glutathione carrying an acetyl group on the cysteine sulfur, and intracellular esterases remove that group to release reduced glutathione. The two are therefore the same active molecule presented differently rather than two separate compounds. Stacking them adds nothing mechanistically that raising the dose of either would not. Worth flagging so a formula does not double-count the same tripeptide.

Cysteine is the rate-limiting amino acid in de novo glutathione synthesis, since glutamate-cysteine ligase depends on its availability. A preformed glutathione derivative bypasses that step, while cysteine feeds the pathway that makes new tripeptide. The two therefore reach the same pool by different routes. This is settled pathway biochemistry, not a combination trial result.

Methionine is converted through homocysteine and cystathionine to cysteine by the transsulfuration pathway, which is the endogenous route to glutathione's limiting amino acid. That pathway depends on cystathionine beta-synthase and cystathionine gamma-lyase, both vitamin B6 enzymes. Methionine availability therefore sits upstream of glutathione synthesis. It says nothing about what a preformed acetylated glutathione then does.

Methionine synthase uses methylcobalamin to remethylate homocysteine back to methionine, which sets how much homocysteine is instead directed down transsulfuration toward cysteine. B12 status therefore shapes the balance between the two fates of homocysteine. The connection to glutathione is one step removed but it is textbook. No combined dosing study is being claimed.

Betaine donates a methyl group to homocysteine through betaine-homocysteine methyltransferase, a folate-independent remethylation route. Like B12 it influences the split between remethylation and transsulfuration, and transsulfuration is the source of cysteine for glutathione. The relationship is upstream and metabolic. A preformed glutathione derivative does not depend on it, which is part of the point.

Sulfite oxidase is a molybdenum-dependent enzyme that handles sulfite generated as sulfur amino acids are catabolised. Loading the sulfur pathway with cysteine-bearing compounds raises flux through that end of the route. Molybdenum status is the cofactor side of that handling. This is cofactor biochemistry and needs no citation.

Pantothenate is the backbone of coenzyme A, and acetyl-CoA is the universal acetyl donor in cell metabolism. The acetyl group cleaved from S-acetyl glutathione enters that same acetyl pool once released. The link is metabolic housekeeping rather than an effect on the tripeptide itself. Included because it explains where the acetyl group goes.

Taurine is an end product of cysteine oxidation through cysteine dioxygenase, so it and glutathione draw on the same cysteine pool. Supplying taurine directly spares cysteine that would otherwise be committed to making it. The two compounds sit on branches of one pathway. This is pathway architecture, not a measured combined outcome.

Silymarin is one of the most frequently co-formulated botanicals in glutathione-support products, and the liver is where the largest glutathione pool sits. Reference sources describe silymarin as influencing hepatic antioxidant handling. Whether the pair adds anything over either alone has not been tested together. Treated as a promising formulation pairing, not a demonstrated synergy.

Curcumin is repeatedly described as an activator of Nrf2 signalling, which controls transcription of glutamate-cysteine ligase and other glutathione-pathway enzymes. That raises the cell's own synthetic capacity, a different lever from supplying preformed tripeptide. The two approaches are complementary in principle. Most of the Nrf2 work is cell and animal based, so this is not human outcome evidence.

EGCG is another widely reported Nrf2 pathway activator acting on the same antioxidant response element machinery. Like curcumin it works by inducing enzymes rather than by donating thiol. Combining an inducer with a preformed thiol covers two different points in the same system. The inducer work is largely preclinical and should be read that way.

Astaxanthin acts inside the lipid phase of membranes while glutathione works in the aqueous cytosol. The two occupy different compartments of the same defence network, which is why they are commonly formulated together. Neither replaces the other. This is compartment chemistry rather than a tested combination.

Ubiquinol is a lipid-phase reductant within the mitochondrial inner membrane, and glutathione is the dominant aqueous-phase thiol buffer. Cells maintain both pools with reducing equivalents ultimately traceable to NADPH and the electron transport chain. Supplying one does not substitute for the other. Included as complementary compartments, not as a demonstrated pairing.

Glutathione reductase regenerates reduced glutathione from its oxidised disulfide using NADPH, and NADPH is produced from NADP that derives from the NAD pool through NAD kinase. Precursors that raise NAD availability therefore sit upstream of glutathione recycling capacity. The chain of steps is established, but whether raising NAD measurably changes the glutathione redox ratio in people is not settled. Marked promising for that reason.

Free ferrous iron catalyses hydroxyl radical formation from hydrogen peroxide, and glutathione both reduces peroxides and can reduce ferric iron back to the ferrous state. The interaction runs in both directions depending on conditions. Co-dosing a high-dose thiol with iron is a modulating relationship worth flagging rather than a straightforward additive one. In vivo iron is protein-bound, which limits how far the test-tube chemistry carries.

Glutathione's free thiol binds copper ions directly and is part of how cells buffer intracellular copper before it reaches its chaperones. A preformed thiol at supplemental dose interacts with that same buffering system. This is coordination chemistry rather than a nutrient interaction demonstrated in a trial. It is listed because the direction matters for anyone dosing both.

Glutathione reductase is a flavoprotein that requires FAD, which is made from riboflavin. Without adequate riboflavin the enzyme that regenerates reduced glutathione from its oxidised form works less well. That makes riboflavin status a determinant of how much of the pool stays in the reduced state. Settled cofactor biochemistry, no citation required.